Profund Advisors LLC Acquires 17,525 Shares of Vaxcyte, Inc. $PCVX

Profund Advisors LLC boosted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 53.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 50,447 shares of the company’s stock after purchasing an additional 17,525 shares during the quarter. Profund Advisors LLC’s holdings in Vaxcyte were worth $2,328,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Vaxcyte by 2.7% during the 3rd quarter. Vanguard Group Inc. now owns 12,320,453 shares of the company’s stock valued at $443,783,000 after purchasing an additional 323,368 shares during the last quarter. Wellington Management Group LLP boosted its stake in Vaxcyte by 1.6% in the third quarter. Wellington Management Group LLP now owns 5,032,771 shares of the company’s stock valued at $181,280,000 after acquiring an additional 77,967 shares during the last quarter. State Street Corp lifted its stake in shares of Vaxcyte by 12.1% during the 2nd quarter. State Street Corp now owns 4,942,235 shares of the company’s stock valued at $160,672,000 after buying an additional 534,552 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its stake in shares of Vaxcyte by 12.2% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 3,784,755 shares of the company’s stock valued at $136,327,000 after buying an additional 411,918 shares in the last quarter. Finally, Westfield Capital Management Co. LP lifted its stake in shares of Vaxcyte by 21.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 3,732,715 shares of the company’s stock valued at $134,452,000 after buying an additional 663,817 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $56.83, for a total transaction of $127,867.50. Following the transaction, the chief operating officer owned 160,744 shares of the company’s stock, valued at $9,135,081.52. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total transaction of $180,000.00. Following the transaction, the chief accounting officer directly owned 28,975 shares in the company, valued at $1,738,500. This represents a 9.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 17,037 shares of company stock valued at $994,899 over the last 90 days. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Stock Up 0.7%

Shares of PCVX stock opened at $48.78 on Wednesday. The company has a 50 day moving average price of $57.09 and a 200-day moving average price of $52.35. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00. The firm has a market capitalization of $7.04 billion, a PE ratio of -7.09 and a beta of 1.30.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the previous year, the company posted ($1.04) EPS. Analysts anticipate that Vaxcyte, Inc. will post -7.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. BTIG Research increased their target price on shares of Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. Wall Street Zen lowered shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Guggenheim reissued a “buy” rating and issued a $116.00 price target on shares of Vaxcyte in a report on Monday, February 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.